Oncotarget

Research Papers:

MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1

Songyu Tian, Mingyue Zhang, Xiuwei Chen, Yunduo Liu and Ge Lou _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:87091-87099. https://doi.org/10.18632/oncotarget.13526

Metrics: PDF 1336 views  |   HTML 2126 views  |   ?  


Abstract

Songyu Tian1, Mingyue Zhang2, Xiuwei Chen1, Yunduo Liu1, Ge Lou1

1Department of Gynecology Oncology, Cancer Hospital of Harbin Medical University, Harin, 150081, Heilongjiang, China

2Department of Anaesthesiology, Cancer Hospital of Harbin Medical University, Harin, 150081, Heilongjiang, China

Correspondence to:

Ge Lou, email: [email protected]

Keywords: ovarian cancer, microRNAs, miR-595, ABCB1

Received: July 25, 2016     Accepted: November 09, 2016     Published: November 23, 2016

ABSTRACT

Ovarian cancer is among the leading cause of cancer-related deaths in females. In this study, we demonstrated that miR-595 expression was downregulated in the ovarian cancer tissues and cell lines. miR-595 expression was lower in the lymph node metastases tissues than in the primary ovarian cancer tissues and normal tissues. Furthermore, miR-595 overexpression suppressed the ovarian cancer cell proliferation, colony formation and invasion and promoted the sensitivity of ovarian cancer cell to cisplatin. We identified ABCB1 as a direct target gene of miR-595 in the ovarian cancer cell. ABCB1 expression was upregulated in the ovarian cancer tissues and cell lines. Morevoer, the expression level of ABCB1 was inversely correlated with miR-595 in the ovarian cancer tissues. In addition, overexpression of ABCB1 decreased the miR-595-overexpressing HO8910PM and SKOV-3 cell sensitivity to cisplatin. Ectopic expression of ABCB1 promoted the miR-595-overexpressing HO8910PM and SKOV-3 cell proliferation, colony formation and invasion. These data suggested that miR-595 acted a tumor suppressor role in ovarian cancer development and increased the sensitivity of ovarian cancer to cisplatin.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13526